Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GRAIL, Inc. stock logo
GRAL
GRAIL
$143.26
+8.1%		$85.11
$41.50
▼
$151.46
$6.40B2.831.42 million shs873,685 shs
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
$94.45
-4.1%		$43.53
$10.94
▼
$104.00
$5.94B2.033.37 million shs2.67 million shs
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$302.96
+0.1%		$291.44
$175.89
▼
$326.63
$6.04B1.14259,162 shs179,227 shs
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
$36.95
+3.7%		$10.50
$0.29
▼
$3.72
$1.57B3.931.22 million shs2.23 million shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GRAIL, Inc. stock logo
GRAL
GRAIL
+8.07%+12.90%+77.83%+107.29%+130.84%
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-4.07%+191.96%+151.87%+145.07%+499.30%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
+0.07%+0.48%+5.59%-5.19%+69.19%
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
0.00%0.00%0.00%0.00%+157.31%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GRAIL, Inc. stock logo
GRAL
GRAIL
$143.26
+8.1%		$85.11
$41.50
▼
$151.46
$6.40B2.831.42 million shs873,685 shs
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
$94.45
-4.1%		$43.53
$10.94
▼
$104.00
$5.94B2.033.37 million shs2.67 million shs
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$302.96
+0.1%		$291.44
$175.89
▼
$326.63
$6.04B1.14259,162 shs179,227 shs
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
$36.95
+3.7%		$10.50
$0.29
▼
$3.72
$1.57B3.931.22 million shs2.23 million shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GRAIL, Inc. stock logo
GRAL
GRAIL
+8.07%+12.90%+77.83%+107.29%+130.84%
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-4.07%+191.96%+151.87%+145.07%+499.30%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
+0.07%+0.48%+5.59%-5.19%+69.19%
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
0.00%0.00%0.00%0.00%+157.31%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
GRAIL, Inc. stock logo
GRAL
GRAIL
2.33
Hold$102.70-28.31% Downside
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
2.63
Moderate Buy$100.436.33% Upside
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
3.00
Buy$337.8911.53% Upside
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest UMRX, GRAL, LGND, and KOD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/2/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$105.00 ➝ $175.00
10/1/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$75.00 ➝ $155.00
9/30/2026
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$103.00
9/28/2026
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$112.00
9/28/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$80.00 ➝ $150.00
9/28/2026
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
Lifesci Capital logo
Lifesci Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$85.00 ➝ $145.00
9/28/2026
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$80.00 ➝ $120.00
9/28/2026
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$58.00 ➝ $96.00
9/25/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$65.00 ➝ $100.00
9/25/2026
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$345.00
9/24/2026
GRAIL, Inc. stock logo
GRAL
GRAIL
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
(Data available from 10/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
GRAIL, Inc. stock logo
GRAL
GRAIL
$165.26M38.72N/AN/A$66.13 per share2.17
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
N/AN/AN/AN/A$2.97 per shareN/A
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$268.09M22.53$7.86 per share38.56$51.68 per share5.86
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
$22.50M69.74N/AN/A$1.04 per share35.53
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
GRAIL, Inc. stock logo
GRAL
GRAIL
-$408.35M-$9.75N/AN/AN/A-236.95%-15.88%-14.02%11/11/2026 (Estimated)
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-$229.97M-$4.19N/AN/AN/AN/A-273.23%-85.48%11/12/2026 (Estimated)
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$124.45M$9.3532.4036.282.4467.88%20.06%11.68%11/5/2026 (Estimated)
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
-$31.83M-$1.04N/AN/AN/A-96.84%-87.78%-52.14%N/A

Latest UMRX, GRAL, LGND, and KOD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-$0.9565-$1.05-$0.0935-$1.05N/AN/A
8/6/2026Q2 2026
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$1.97$2.37+$0.40$2.22$61.30 million$63.69 million
8/5/2026Q2 2026
GRAIL, Inc. stock logo
GRAL
GRAIL
-$2.66-$2.56+$0.10-$2.56$42.39 million$44.69 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
GRAIL, Inc. stock logo
GRAL
GRAIL
N/AN/AN/AN/AN/A
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
N/AN/AN/AN/AN/A
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
N/AN/AN/AN/AN/A
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
GRAIL, Inc. stock logo
GRAL
GRAIL
N/A
10.95
10.95
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
N/A
2.49
2.49
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
1.16
31.18
30.96
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
0.18
2.90
2.90

Institutional Ownership

CompanyInstitutional Ownership
GRAIL, Inc. stock logo
GRAL
GRAIL
N/A
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
89.06%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
91.28%
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
26.39%

Insider Ownership

CompanyInsider Ownership
GRAIL, Inc. stock logo
GRAL
GRAIL
1.83%
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
44.40%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
5.60%
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
31.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
GRAIL, Inc. stock logo
GRAL
GRAIL
91044.67 million43.85 millionOptionable
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
12462.85 million34.94 millionOptionable
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
4719.94 million18.82 millionOptionable
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
7242.47 millionN/ANot Optionable

Recent News About These Companies

Cogent Biosciences, Inc. Announces FDA Acceptance Of New Drug Application For Bezuclastinib In Patients With Advanced Systemic Mastocytosis
September 15, 2026  |  marketscreener.comM
Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
September 15, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/cogent-biosciences-announces-fda-acceptance-120000587.html
Cogent Bio granted third FDA review for lead asset
September 15, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4642917-cogent-bio-wins-third-fda-review-lead-asset
Cogent Biosciences Inc.
September 13, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/cogt/company-people?gaa_at=eafs&gaa_n=AWEtsqda378-vBiPTHtk94vHD9sMtP4wHndKNlqrwi2R0J6z-XYJiH52emwW&gaa_ts=69d52197&gaa_sig=z9mvEEUYDYwDFLbhRjgzd0WXiOGTlP2Ne0STKoamCVrXzUAif8d6koMnBafiy1RRjBFI-thdh9XiTH6orPz-Ug%253D%253D
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results
August 10, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/cogent-biosciences-reports-recent-business-highlights-and-second-quarter-2026-financial-results-1036435465
Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 ...
May 30, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/cogent-biosciences-announces-detailed-clinical-data-from-peak-phase-3-trial-with-bezuclastinib-in-combination-with-sunitinib-in-gastrointestinal-stromal-tumors-gist-at-2026-american-society-of-1036209656
Cogent Bio granted FDA priority review for lead asset in tumor indication
May 28, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4597892-cogent-granted-fda-priority-review-for-lead-asset
Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO ...
April 21, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/cogent-biosciences-announces-oral-presentation-of-positive-phase-3-peak-trial-in-gastrointestinal-stromal-tumors-gist-at-the-2026-american-society-of-clinical-oncology-asco-annual-meeting-1036042508
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)
April 1, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/cogent-biosciences-announces-submission-of-new-drug-application-for-bezuclastinib-in-gastrointestinal-stromal-tumors-gist-1035985261
Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)
March 16, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/cogent-biosciences-announces-fda-acceptance-of-new-drug-application-for-bezuclastinib-in-patients-with-nonadvanced-systemic-mastocytosis-nonadvsm-1035932701
Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough
February 17, 2026  |  fool.comhttps://www.fool.com/coverage/filings/2026/02/17/cogent-biosciences-stock-up-346-as-fund-builds-usd29-million-stake-after-november-phase-3-breakthrough/
Cogent Biosciences submits NDA for bezuclastinib in NONADVSM
December 30, 2025  |  msn.comhttps://www.msn.com/en-us/money/other/cogent-biosciences-submits-nda-for-bezuclastinib-in-nonadvsm/ar-AA1Tisr9
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis
December 30, 2025  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2025/12/30/10310068.htm
Cogent Biosciences: Time For A Pause
December 15, 2025  |  seekingalpha.comhttps://seekingalpha.com/article/4853525-cogent-biosciences-time-for-a-pause
Cogent Biosciences price target raised to $48 from $45 at Jefferies
December 8, 2025  |  msn.comhttps://www.msn.com/en-us/money/markets/cogent-biosciences-price-target-raised-to-48-from-45-at-jefferies/ar-AA1RXhi2
Cogent Biosciences jumps after strong late-stage results in advanced systemic mastocytosis
December 8, 2025  |  msn.comhttps://www.msn.com/en-us/money/other/cogent-biosciences-jumps-after-strong-late-stage-results-in-advanced-systemic-mastocytosis/ar-AA1RWwKu
Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
December 8, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/cogent-biosciences-announces-positive-top-line-results-of-apex-trial-of-bezuclastinib-in-patients-with-advanced-systemic-mastocytosis-advsm-1035625401
Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American ...
December 6, 2025  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2025/12/06/10301319.htm
HC Wainwright & Co. Maintains Cogent Biosciences (COGT) Buy Recommendation
November 14, 2025  |  msn.comhttps://www.msn.com/en-us/money/topstocks/hc-wainwright-co-maintains-cogent-biosciences-cogt-buy-recommendation/ar-AA1QpPe9
Cogent Biosciences price target raised to $50 from $21 at H.C. Wainwright
November 13, 2025  |  msn.comhttps://www.msn.com/en-us/money/other/cogent-biosciences-price-target-raised-to-50-from-21-at-h-c-wainwright/ar-AA1QnC30

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Micron, Coherent and Tower Semiconductor: 3 Stocks Built on AI's Bottlenecks
NVIDIA Just Named AI's Next Bottleneck—And These 3 Stocks Sit Right In It
By Bridget Bennett | September 20, 2026
A Tesla concept vehicle with illuminated front light bar drives on a road against a city skyline at dusk.
Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
By Sam Quirke | September 8, 2026
Data center hallway with rows of server racks and cables, plus a monitoring room with computer screens in the background.
AI Token Costs Are Changing the Hardware vs. Software Debate
By Jeffrey Neal Johnson | September 6, 2026
Stacks of coins rising on a desk beside a computer with an upward stock chart, with a blurred city skyline behind.
3 Dividend Kings to Buy While They’re Still Beaten Down
By Thomas Hughes | September 14, 2026
Microscope and test tubes beside a laptop showing a rising chart signal biotech progress and improving stock momentum.
3 Small-Cap Biotechs With Binary Catalysts on the Calendar
By Chris Markoch | September 13, 2026
GRAIL stock logo

GRAIL NASDAQ:GRAL

$143.26 +10.70 (+8.07%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$142.72 -0.54 (-0.38%)
As of 10/2/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

Kodiak Sciences stock logo

Kodiak Sciences NASDAQ:KOD

$94.45 -4.01 (-4.07%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$94.29 -0.16 (-0.17%)
As of 10/2/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Ligand Pharmaceuticals stock logo

Ligand Pharmaceuticals NASDAQ:LGND

$302.96 +0.22 (+0.07%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$303.06 +0.10 (+0.03%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Cogent Biosciences stock logo

Cogent Biosciences NASDAQ:UMRX

Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas